AzurRx BioPharma

100 articles with AzurRx BioPharma

• AzurRx BioPharma to Change Corporate Name to First Wave BioPharma TodayCompany to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22

  9/21/2021

  AzurRx BioPharma, Inc. announced that it will begin operating under its new corporate name, First Wave BioPharma, Inc., effective today upon the completion of certain filings with the Delaware Secretary of State.

• AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

  9/14/2021

  AzurRx BioPharma, Inc. today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name.

• 

  Clinical Catch-Up: September 6-10

  9/13/2021

  It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.
• 

  AzurRx Carves Out Slice of IBD Market in $229 Million Buyout

  9/13/2021

  AzurRx will change its name to First Wave BioPharma, Inc., and the company’s shares will trade on the Nasdaq under the ticker symbol “FWBI.”

• AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

  9/13/2021

  AzurRx BioPharma, Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that it has entered a definitive agreement to acquire First Wave Bio, Inc. in a stock and cash transaction valued at $229 million, including certain development, regulatory and sales milestones.

• AzurRx BioPharma Announces Reverse Stock SplitCommon Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021

  9/10/2021

  AzurRx BioPharma, Inc. announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.

• AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

  9/10/2021

  AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, therapies for gastrointestinal diseases, announced the activation of seven new clinical trial sites in India for the ongoing RESERVOIR trial evaluating FW-1022.

• AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

  9/9/2021

  AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), today announced that an independent data monitoring committee (DMC) approved initiating patient enrollment in Part 2 of the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal (GI) infections.

• AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor

  9/8/2021

  AzurRx BioPharma, Inc. announced today the submission of an Investigational New Drug (IND) Application seeking permission from the U.S. Food and Drug Administration (FDA) to begin a clinical trial

• AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chief Executive Officer of AzurRx, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

• AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

  8/18/2021

  AzurRx BioPharma, Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced positive topline results from its Phase 2 Combination Trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy, for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis.

• AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819

  8/17/2021

  AzurRx BioPharma, Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced the World Health Organization has published “adrulipase alfa” as the proposed International Nonproprietary Name for MS1819.

• 

  Clinical Catch-Up: August 9-13

  8/16/2021

  There was plenty of clinical trial updates last week. Here’s a look.

• AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

  8/12/2021

  AzurRx BioPharma, Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that it has completed enrollment of the initial cohort into Part 1 of its ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections.

• AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

  8/10/2021

  AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal diseases, announced the completion of site initiation visits and the addition of five new clinical trial sites in Ukraine for the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections.

• AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter’s Option to Purchase Additional Shares

  7/27/2021

  AzurRx BioPharma, Inc. announced the closing of its previously announced underwritten public offering of 10,454,546 shares of common stock of the Company, including the exercise in full by the underwriter of the option to purchase an additional 1,363,636 shares of common stock, at a price to the public of $0.55 per share.

• AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million

  7/23/2021

  AzurRx BioPharma, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9,090,910 shares of common stock of the Company, at a price to the public of $0.55 per share, less underwriting discounts and commissions.

• AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock

  7/22/2021

  AzurRx BioPharma, Inc. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 5,454,546 shares of common stock of the Company, at a price to the public of $0.55 per share, less underwriting discounts and commissions.

• 

  Clinical Catch-Up: June 7-11

  6/14/2021

  A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.

• AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital

  6/8/2021

  AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that James Sapirstein, Chief Executive Officer of AzurRx, will present at the 2021 BIO Digital.